The Pharma Data

APRIL 28, 2021

OSAKA, Japan, April 28, 2021 – Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that it was awarded by the International Society for Pharmaceutical Engineering (ISPE) for the 2021 Facility Of the Year Awards (FOYA) in two categories.

Packaging 52

Packaging Small Molecule Pharmaceutical Companies Engineering 52

The Pharma Data

DECEMBER 9, 2020

With the expected Emergency Use Authorization (EUA) of Pfizer – BioNTech and Moderna ’s COVID-19 vaccines providing hope that the COVID-19 pandemic will soon be resolved, 2021 is going to need a new primary healthcare campaign. Could it come from the field of neuroscience? in a statement. . Tranquis Therapeutics.

Marketing 52

Marketing Small Molecule Disease Pharmaceuticals 52

The Pharma Data

JANUARY 10, 2021

I actually think neuroscience is going to heat up in 2021,” said Ben Zeskind , co-founder and CEO of Immuneering , which is using bioinformatics and computational biology to develop new drugs in this space, along with oncology and immuno-oncology. In a boone for Slonim’s research focus, the year 2020 has made this molecule a household name.

Vaccine 52

Vaccine Disease Regulations Small Molecule 52

The Pharma Data

AUGUST 3, 2021

Revenue in the second quarter of 2021 increased 23 percent, driven by volume growth of 22 percent. – Revenue from all key products grew in the quarter and 2021 year-to-date. . – Revenue from all key products grew in the quarter and 2021 year-to-date. – 2021 EPS guidance updated to be in the range of $6.73

Production 52

Production Marketing Research DNA 52

Drug Target Review

JUNE 19, 2024

Our goal is to stand on the shoulders of giants and advance this exciting and new field of medicine, so that it can deliver valuable treatments to patients. Transplanting cells could prove to be more beneficial than treating a particular condition with a small molecule or an antibody, and that really speaks to the power of cell therapy.

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

The Pharma Data

AUGUST 3, 2021

today announced financial results for the second quarter of 2021. 2021 total revenues guidance reaffirmed at $25.8-$26.6 COVID-19 update : Compared to the first quarter of 2021, we have seen gradual recovery from the impacts of the COVID-19 pandemic. Key results include: Total revenues increased 5% to $6.5 on a non-GAAP basis.

Biosimilars 52

Biosimilars Production Treatment FDA 52

The Pharma Data

JANUARY 25, 2021

26, 2021 13:00 UTC. –( BUSINESS WIRE )– Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced that the U.S. FREDERICK, Md.–( About VLX-1005.

FDA 52

FDA Small Molecule FDA Approval Drugs 52

The Pharma Data

JANUARY 31, 2021

1, 2021 12:16 UTC. Patent US10835501B2, which relates to pharmaceutical compositions comprising a statin and a cannabinoid, and their use for the treatment of hypercholesterolemia and atherosclerosis. Cannabinoids are a diverse class of small molecules that interact on the g-coupled receptor subtypes CB1 and CB2.

Small Molecule 52

Small Molecule Therapies Clinical Research Pharmaceuticals 52

The Pharma Data

JANUARY 10, 2021

11, 2021 /PRNewswire/ — On January 8, 2021 , Shenzhen Chipscreen Biosciences Co., Comparing to Non-Small Cell Lung Cancer(NSCLC), it is still not clear about tumor driving gene in the development of SCLC, and thus it is lacking of targeted therapeutic treatment for this life threaten disease. SHENZHEN, China , Jan.

Clinical Trials 52

Clinical Trials Treatment Trials Small Molecule 52

New Drug Approvals

SEPTEMBER 29, 2024

link] 01 Aug 2022 Cortexyme is now called Quince Therapeutics You need to be a logged in or subscribed to view this content This small molecule is an orally available protease inhibitor targeting the lysine proteases of the periodontal pathogen Porphyromonas gingivalis. In preclinical work from other labs, infection with P. and Europe.

Small Molecule 62

Small Molecule DNA Disease Trials 62

The Pharma Data

AUGUST 7, 2021

Vividion’s platform is able to produce a variety of small molecule therapies across indications, with initial focus on targets relevant to oncology and immunology. The acquisition of Vividion strengthens Bayer’s small molecule capabilities and expands Bayer’s reach into new modalities.

Small Molecule 52

Small Molecule Drugs Therapies Disease 52

Drug Target Review

JUNE 12, 2023

With 13 preclinical candidates and three AI-designed drugs currently undergoing clinical trials, Insilico is spearheading a revolution in cancer treatment and beyond. Can you provide a summary of the key findings and implications of the preclinical studies on ISM6331 for the treatment of advanced solid tumours?

Metabolic Stability 92

Metabolic Stability Clinical Trials Small Molecule Pharmacokinetics 92

The Pharma Data

OCTOBER 15, 2020

Vertex Pharmaceuticals has decided to give up on its experimental VX-814, a small molecule drug for the rare genetic disease Alpha-1 antitrypsin deficiency (AATD), canning the drug’s development after seeing lackluster results from an early phase 2 trial.

Disease 52

Disease Small Molecule Pharmacokinetics Licensing 52

Drug Target Review

JULY 7, 2023

In pregnant individuals, maternal autoantibodies can even attack the organs and tissues of the foetus, 1-9 Many of these diseases are rare, with no safe, targeted, advanced and effective treatment options approved for patients in need. By stopping or blocking the normal work of these molecules, diseases can often be slowed or even stopped.

Disease 98

Disease Immune Response Therapies Treatment 98

The Pharma Data

DECEMBER 15, 2020

FDA Approves Klisyri (tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp. NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the U.S. BUFFALO, N.Y.,

FDA Approval 52

FDA Approval FDA Treatment Therapies 52

The Pharma Data

APRIL 27, 2021

Paris, April 28, 2021. Strong increase in Q1 2021 business EPS ( 1) at CER. Q1 2021 sales increase of 2.4% Q1 2021 business EPS ( 1) growth at CER driven by efficiency and sales performance, supported by a one-time payment. Sanofi has become a member of the top five companies of the 2021 Access to Medicine index.

Vaccine 52

Vaccine Production FDA Disease 52

The Pharma Data

JANUARY 13, 2021

14, 2021 11:00 UTC. These Phase 2 results strongly support the continued development of dexpramipexole as a potential first-in-class oral agent for the treatment of eosinophilic asthma,” said Michael Bozik, M.D., Background standard of care was inhaled corticosteroids in combination with a long-acting ?2 President and CEO of Knopp. “We

Trials 52

Trials Small Molecule Clinical Trials Treatment 52

The Pharma Data

MARCH 25, 2021

The study included an active control arm where patients were treated with dupilumab, a biologic treatment administered by subcutaneous injection. The manuscript was published in the March 25, 2021 issue of NEJM. Abrocitinib is an oral small molecule that selectively inhibits Janus kinase (JAK) 1. About Abrocitinib.

Small Molecule 52

Small Molecule Therapies Treatment Disease 52

The Pharma Data

JANUARY 19, 2021

19, 2021 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. The offering is expected to close on January 22, 2021, subject to customary closing conditions. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and Phase 3 for the treatment of COVID-19.

Small Molecule 40

Small Molecule Clinical Development Treatment Disease 40

The Pharma Data

NOVEMBER 15, 2020

In a deal set to be finalized early in 2021, Urovant Sciences has agreed to be fully acquired by largest investor and close partner, Sumitovant Biopharma. Sumitovant is a global biopharmaceutical company with a pipeline similarly focused on uterine fibroids, advanced prostate cancer and endometriosis. .

Science 52

Science Small Molecule FDA Approval Therapies 52

The Pharma Data

JANUARY 18, 2021

18, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. The fireside chat is scheduled to take place on Wednesday, January 20, 2021 at 2:30 PM ET. The fireside chat is scheduled to take place on Wednesday, January 20, 2021 at 2:30 PM ET. for the treatment of post-herpetic neuralgia. SAN DIEGO, Jan.

Clinical Trials 40

Clinical Trials Small Molecule Trials Therapies 40

The Pharma Data

JANUARY 13, 2021

GMP Production of TNX-1500 is Expected to be Available in the Third Quarter of 2021. 14, 2021 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals, Inc. WO 2021/001458 A1. We are developing the manufacturing processes for TNX-1500 and expect Good Manufacturing Practice (GMP) TNX-1500 to be available in the third quarter of 2021.

Pharmaceuticals 52

Pharmaceuticals Small Molecule Vaccine Protein Expression 52

Drug Target Review

MAY 23, 2023

Therapies developed in recent decades have transformed the treatment of IBD, making hospitalisation and surgery less common. However, many patients respond poorly to corticosteroid treatment, or their immune system responds unfavourably to biological therapies, such as the development of autoimmune diseases.

Drugs 75

Drugs Small Molecule Production Disease 75

The Pharma Data

JANUARY 26, 2021

27, 2021 /PRNewswire/ — Q Biomed Inc. Food and Drug Administration’s Office of Orphan Products Development has granted Orphan Drug Designation to Uttroside-B , a small molecule chemotherapeutic for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. .

FDA 40

FDA Treatment Small Molecule Drugs 40

LifeSciVC

AUGUST 5, 2024

But that initial quote isn’t from 2024, it is from an interview in 2021 with Mark Levin, CEO at Millennium (MIT Technology Review). The proteosome inhibitor, approved for treatment of multiple myeloma and mantle cell lymphoma, has been an important medicine for patients but it isn’t a product of the genomics revolution.

Molecular Biology 85

Molecular Biology Production Drug Development Small Molecule 85

The Pharma Data

SEPTEMBER 8, 2021

Adds Rezurock™ (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy. Sanofi has entered into a definitive merger agreement with Kadmon Holdings, Inc. Cantor Fitzgerald & Co.

FDA Approval 52

FDA Approval Therapies Small Molecule FDA 52

The Pharma Data

JANUARY 31, 2021

1, 2021 /PRNewswire/ — AIkido Pharma Inc. Convergent is currently conducting advanced human trials relating to prostate cancer treatments involving peptide receptor radionuclide therapy (“PRRT”) that targets the prostate-specific membrane antigen (“PSMA”) present on prostate cancer cells.

Small Molecule 40

Small Molecule FDA Approval Therapies Trials 40

New Drug Approvals

SEPTEMBER 10, 2024

g/mol 1929519-13-0 NBI-1065846 or TAK-041 Phase 2 (S)-2-(4-oxobenzo[d][1,2,3]triazin-3(4H)-yl)-N-(1-(4-(trifluoromethoxy)phenyl)ethyl)acetamide Zelatriazin ( NBI-1065846 or TAK-041 ) is a small-molecule agonist of GPR139. Cilia, Jackie; Hitchcock, Stephen (12 August 2021). Zelatriazin, C 18 H 15 F 3 N 4 O 3 , 392.3 1c00820.

Clinical Pharmacology 62

Clinical Pharmacology Small Molecule Pharmacokinetics Pharmaceutical Companies 62

The Pharma Data

MARCH 4, 2021

The new agreement is expected to close by end of March 2021, subject to the satisfaction of customary closing conditions, including review by the appropriate regulatory agencies under the Hart-Scott-Rodino Act. “I Advancing New Treatment Options for DS and LGS Patients. About Soticlestat (TAK-935/OV935).

Treatment 52

Treatment Clinical Trials Pharmaceutical Companies Trials 52

The Pharma Data

JANUARY 7, 2021

Pivotal Data Anticipated in 2021 to Support Potential Registration, Addressing an Estimated Market Opportunity of Greater than $500 Million. ONC201 is currently in a registrational clinical trial for recurrent H3 K27M-mutant glioma and a confirmatory response rate assessment is expected in 2021. ET Today.

Clinical Trials 52

Clinical Trials Small Molecule Trials Therapies 52

The Pharma Data

OCTOBER 21, 2020

Importantly, the manufacturing process for our small molecule direct-acting antiviral allows us to produce AT-527 quickly and at scale.”. “In jointly developing and manufacturing AT-527 at scale, we seek to make this treatment option available to as many people around the world as we possibly can.” BOSTON, Oct.

RNA 52

RNA Pharmaceuticals Virus Clinical Trials 52

The Pharma Data

JANUARY 18, 2021

Interim Analysis on Part 1 is expected in Q1 2021. The COVA Study assesses Sarconeos (BIO101) as a potential treatment for acute respiratory failure associated with COVID-19. A pediatric formulation of Sarconeos (BIO101) is being developed for the treatment of Duchenne Muscular Dystrophy (DMD).

Small Molecule 52

Small Molecule Hospitals Treatment Clinical Trials 52

The Pharma Data

JANUARY 6, 2021

7, 2021 11:00 UTC. SAN DIEGO–( BUSINESS WIRE )– Endeavor BioMedicines , a biotechnology company developing new treatments targeting the underlying causes of pulmonary fibrosis, today announced it has raised $62 million in a Series A financing. Taladegib is a small-molecule inhibitor of the Hedgehog signaling pathway.

Disease 40

Disease Small Molecule Treatment Therapies 40

KIF1A

MAY 27, 2023

Lessard created and advanced KIF1A.ORG’s Therapeutic Acceleration Program, facilitating the creation of patient-derived cell lines, mouse models, and drug screening platforms that are the bedrock of our search for treatments. Read more to learn about the factors involved in incentivizing investment in rare disease treatments.

Science 94

Science Small Molecule Disease Research 94

The Pharma Data

JUNE 22, 2023

As the global leader in cell therapy, we appreciate the opportunity and responsibility of bringing this innovative treatment to as many eligible patients as possible who may benefit,” said Cindy Perettie, Executive Vice President and Global Head of Kite. “We Kite’s manufacturing facility in El Segundo, California, U.S. Source link: [link]

Therapies 40

Therapies Marketing Small Molecule Science 40

The Pharma Data

JULY 15, 2021

The company’s proprietary chemical biology-based platform enables the development of therapeutic peptides and proteins with tunable activity that can be controlled using small molecules. There will be no change to Lilly’s 2021 non-GAAP earnings per share guidance as a result of this transaction. Aquilo Partners, L.P.

Small Molecule 52

Small Molecule Engineering Therapies Science 52

KIF1A

JUNE 30, 2023

KAND and Spasticity : We created this resource to help families understand mechanisms of spasticity in KAND, including considerations between different treatment options. With your support, KIF1A.ORG continues to bring together the expertise and innovation needed to rapidly discover treatments and cures for KAND.

Small Molecule 52

Small Molecule Treatment Doctors Research 52